GERMANTOWN, Md., May 1, 2013 /PRNewswire/ -- Intrexon Corporation, a next generation synthetic biology company, today announced that it has closed a Series F preferred investment round of $150 million, bringing the company's total capital raised to $509 million. New investors accounted for the majority of the round, with current investors, including affiliates of Randal J. Kirk , Intrexon's Chairman and CEO, and Third Security, LLC, taking the balance of the round.
The funding will be used to provide working capital for the establishment of additional exclusive channel collaborations in Intrexon's core sectors, including Healthcare, Food, Energy and Environment, continued development of the company's industry-leading technology platforms, expansion of sales and marketing, and research and development.
"The Intrexon team is committed to delivering results for all of our collaborations," said Mr. Kirk. "With our proprietary technology platforms, we are helping our collaborators discover, design, develop and ultimately bring to market genetically-enhanced products that hold remarkable promise."
Mr. Kirk added, "It is especially gratifying to our entire team that, in addition to being our largest investment series to date, a majority of the investment came from new investors who share our vision."
About Intrexon CorporationIntrexon Corporation is a privately held biotechnology company focused on the industrial engineering of synthetic biology. Intrexon is deploying its extensive capabilities to rapidly design and produce novel and enhanced biological products and processes across multiple industry sectors, including: human therapeutics, protein production, industrial products, agricultural biotechnology, and animal science. The company's advanced bioindustrial engineering platform enables Better DNA™ technology by combining revolutionary DNA control syste
|SOURCE Intrexon Corporation|
Copyright©2012 PR Newswire.
All rights reserved